WDR7
geneOn this page
Also known as KIAA0541TRAG
Summary
WDR7 (WD repeat domain 7, HGNC:13490) is a protein-coding gene on chromosome 18q21.31, encoding WD repeat-containing protein 7 (Q9Y4E6). It is a selective cancer dependency (DepMap: 80.1% of cell lines).
This gene encodes a member of the WD repeat protein family. WD repeats are minimally conserved regions of approximately 40 amino acids typically bracketed by gly-his and trp-asp (GH-WD) that may facilitate formation of heterotrimeric or multiprotein complexes. Members of this family are involved in a variety of cellular processes, including cell cycle progression, signal transduction, apoptosis, and gene regulation. The encoded protein forms the beta subunit of rabconnectin-3 and binds directly with Rab3A GDP/GTP exchange protein and indirectly with Rab3A GDP/GTP activating protein; these proteins are regulators of Rab3 small G protein family members involved in control of the calcium-dependant exocytosis of neurotransmitters. Alternatively spliced transcript variants encoding different isoforms have been described.
Source: NCBI Gene 23335 — RefSeq curated summary.
At a glance
- GWAS associations: 8
- Clinical variants (ClinVar): 211 total
- Cancer dependency (DepMap): dependent in 80.1% of screened cell lines
- MANE Select transcript:
NM_015285
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:13490 |
| Approved symbol | WDR7 |
| Name | WD repeat domain 7 |
| Location | 18q21.31 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | KIAA0541, TRAG |
| Ensembl gene | ENSG00000091157 |
| Ensembl biotype | protein_coding |
| OMIM | 613473 |
| Entrez | 23335 |
Gene structure
Transcript identifiers
Ensembl transcripts: 12 — 5 protein_coding, 4 protein_coding_CDS_not_defined, 2 retained_intron, 1 nonsense_mediated_decay
ENST00000254442, ENST00000357574, ENST00000585669, ENST00000585754, ENST00000585824, ENST00000586124, ENST00000587403, ENST00000589935, ENST00000590557, ENST00000591449, ENST00000591524, ENST00000593058
RefSeq mRNA: 4 — MANE Select: NM_015285
NM_001382485, NM_001382487, NM_015285, NM_052834
CCDS: CCDS11962, CCDS11963
Canonical transcript exons
ENST00000254442 — 28 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000669580 | 56756583 | 56757352 |
| ENSE00000669586 | 56816031 | 56816144 |
| ENSE00000903368 | 56672497 | 56672674 |
| ENSE00000903369 | 56679332 | 56679438 |
| ENSE00000903370 | 56681313 | 56681391 |
| ENSE00000903371 | 56682679 | 56682853 |
| ENSE00000903372 | 56685956 | 56686032 |
| ENSE00000903373 | 56691216 | 56691361 |
| ENSE00000903374 | 56691715 | 56691817 |
| ENSE00000903379 | 56776782 | 56776880 |
| ENSE00000903381 | 56781533 | 56781656 |
| ENSE00000903382 | 56879944 | 56880165 |
| ENSE00000903388 | 57020745 | 57020849 |
| ENSE00001106377 | 56717964 | 56718159 |
| ENSE00001106388 | 56686855 | 56686974 |
| ENSE00001160173 | 56696242 | 56696462 |
| ENSE00001160188 | 56694619 | 56694760 |
| ENSE00003512028 | 56779431 | 56779549 |
| ENSE00003571082 | 56694950 | 56695198 |
| ENSE00003574482 | 56731383 | 56731597 |
| ENSE00003583196 | 56938533 | 56938682 |
| ENSE00003599485 | 56962430 | 56962529 |
| ENSE00003616881 | 56939311 | 56939393 |
| ENSE00003665528 | 56758865 | 56758953 |
| ENSE00003733187 | 57027004 | 57029792 |
| ENSE00003745376 | 56935788 | 56935905 |
| ENSE00003747193 | 56923922 | 56924108 |
| ENSE00003909649 | 56651359 | 56651576 |
Expression profiles
Bgee: expression breadth ubiquitous, 288 present calls, max score 98.31.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.1048 / max 172.2434, expressed in 1764 samples.
FANTOM5 promoters (6 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 170337 | 10.9503 | 1744 |
| 170340 | 2.5035 | 591 |
| 170339 | 1.4078 | 683 |
| 170338 | 0.1806 | 65 |
| 170341 | 0.0325 | 17 |
| 170342 | 0.0301 | 16 |
Top tissues by expression
299 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| endothelial cell | CL:0000115 | 98.31 | gold quality |
| middle temporal gyrus | UBERON:0002771 | 97.79 | gold quality |
| Brodmann (1909) area 23 | UBERON:0013554 | 97.26 | gold quality |
| Brodmann (1909) area 10 | UBERON:0013541 | 97.07 | gold quality |
| frontal pole | UBERON:0002795 | 97.03 | gold quality |
| postcentral gyrus | UBERON:0002581 | 95.09 | gold quality |
| lateral nuclear group of thalamus | UBERON:0002736 | 95.07 | gold quality |
| parietal lobe | UBERON:0001872 | 94.74 | gold quality |
| orbitofrontal cortex | UBERON:0004167 | 94.51 | gold quality |
| pons | UBERON:0000988 | 94.32 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 94.32 | gold quality |
| CA1 field of hippocampus | UBERON:0003881 | 94.08 | gold quality |
| Brodmann (1909) area 46 | UBERON:0006483 | 94.07 | gold quality |
| entorhinal cortex | UBERON:0002728 | 93.97 | gold quality |
| corpus callosum | UBERON:0002336 | 93.68 | gold quality |
| paraflocculus | UBERON:0005351 | 93.39 | gold quality |
| middle frontal gyrus | UBERON:0002702 | 93.37 | gold quality |
| substantia nigra pars compacta | UBERON:0001965 | 93.32 | gold quality |
| calcaneal tendon | UBERON:0003701 | 92.94 | gold quality |
| cerebellar vermis | UBERON:0004720 | 92.80 | gold quality |
| superior vestibular nucleus | UBERON:0007227 | 92.70 | gold quality |
| choroid plexus epithelium | UBERON:0003911 | 92.48 | gold quality |
| primary visual cortex | UBERON:0002436 | 92.44 | gold quality |
| occipital lobe | UBERON:0002021 | 92.18 | gold quality |
| substantia nigra pars reticulata | UBERON:0001966 | 92.05 | gold quality |
| prefrontal cortex | UBERON:0000451 | 91.64 | gold quality |
| medulla oblongata | UBERON:0001896 | 91.34 | gold quality |
| dorsal motor nucleus of vagus nerve | UBERON:0002870 | 91.29 | gold quality |
| lateral globus pallidus | UBERON:0002476 | 91.28 | gold quality |
| inferior olivary complex | UBERON:0002127 | 90.90 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-GEOD-124858 | no | 191.30 |
| E-ANND-3 | no | 7.32 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): BRD1
Functional genomics
DepMap (CRISPR cell-line fitness): dependent in 80.1% of screened cell lines.
Literature-anchored findings (GeneRIF, showing 1)
- Evolution of a Human-Specific Tandem Repeat Associated with ALS. (PMID:32750315)
Cross-species orthologs
7 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | WDR7 | ENSDARG00000100274 |
| danio_rerio | ENSDARG00000107858 | |
| danio_rerio | ENSDARG00000112868 | |
| mus_musculus | Wdr7 | ENSMUSG00000040560 |
| rattus_norvegicus | Wdr7 | ENSRNOG00000018387 |
| drosophila_melanogaster | Rbcn-3B | FBGN0023510 |
| caenorhabditis_elegans | WBGENE00004314 |
Paralogs (26): PAFAH1B1 (ENSG00000007168), SNRNP40 (ENSG00000060688), WDR62 (ENSG00000075702), TBL2 (ENSG00000106638), PAK1IP1 (ENSG00000111845), WDR75 (ENSG00000115368), DCAF4 (ENSG00000119599), DAW1 (ENSG00000123977), TEP1 (ENSG00000129566), AHI1 (ENSG00000135541), WDR38 (ENSG00000136918), MAPKBP1 (ENSG00000137802), POC1B (ENSG00000139323), NEDD1 (ENSG00000139350), COP1 (ENSG00000143207), WDR17 (ENSG00000150627), WDR43 (ENSG00000163811), POC1A (ENSG00000164087), WDR88 (ENSG00000166359), WDR81 (ENSG00000167716), DCAF4L2 (ENSG00000176566), DCAF4L1 (ENSG00000182308), WDR27 (ENSG00000184465), NWD1 (ENSG00000188039), WDR5 (ENSG00000196363), WDR5B (ENSG00000196981)
Protein
Protein identifiers
WD repeat-containing protein 7 — Q9Y4E6 (reviewed: Q9Y4E6)
Alternative names: Rabconnectin-3 beta, TGF-beta resistance-associated protein TRAG
All UniProt accessions (5): Q9Y4E6, K7EMB8, K7EMF3, K7EPQ4, K7EPY9
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9Y4E6-1 | 1 | yes |
| Q9Y4E6-2 | 2 |
RefSeq proteins (4): NP_001369414, NP_001369416, NP_056100, NP_443066 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR001680 | WD40_rpt | Repeat |
| IPR011047 | Quinoprotein_ADH-like_sf | Homologous_superfamily |
| IPR015943 | WD40/YVTN_repeat-like_dom_sf | Homologous_superfamily |
| IPR019775 | WD40_repeat_CS | Conserved_site |
| IPR036322 | WD40_repeat_dom_sf | Homologous_superfamily |
| IPR049916 | WDR72-like | Family |
| IPR057848 | WDR72_alpha-sol | Domain |
Pfam: PF00400, PF23123
UniProt features (18 total): repeat 9, region of interest 2, compositionally biased region 2, modified residue 2, chain 1, splice variant 1, sequence conflict 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9Y4E6-F1 | 74.31 | 0.36 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (2): 935, 1456
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 178 (showing top):
GOBP_HEMATOPOIETIC_PROGENITOR_CELL_DIFFERENTIATION, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, MODULE_66, GOBP_VACUOLAR_ACIDIFICATION, DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN, SCHLOSSER_SERUM_RESPONSE_DN, HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP, MODULE_88, GOBP_REGULATION_OF_PH, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, GOBP_MONOATOMIC_ION_HOMEOSTASIS, MODULE_6, MODULE_11, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN
GO Biological Process (1): hematopoietic progenitor cell differentiation (GO:0002244)
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (1): cytoplasm (GO:0005737)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| hemopoiesis | 1 |
| cell differentiation | 1 |
| binding | 1 |
| intracellular anatomical structure | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
1850 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| WDR7 | DMXL2 | Q8TDJ6 | 978 |
| WDR7 | NCOR2 | Q9Y618 | 856 |
| WDR7 | RAB3GAP2 | Q9H2M9 | 832 |
| WDR7 | MADD | Q8WXG6 | 808 |
| WDR7 | RAB3A | P20336 | 791 |
| WDR7 | VMA22 | Q96NT0 | 738 |
| WDR7 | DNAJC5 | Q9H3Z4 | 641 |
| WDR7 | ATP6V1C1 | P21283 | 576 |
| WDR7 | ROGDI | Q9GZN7 | 560 |
| WDR7 | DMXL1 | Q9Y485 | 545 |
| WDR7 | ATP6V1H | Q9UI12 | 534 |
| WDR7 | TSNAX | Q99598 | 514 |
| WDR7 | ATP6V1E1 | P36543 | 511 |
| WDR7 | DNAJC28 | Q9NX36 | 469 |
| WDR7 | SGMS1 | Q86VZ5 | 462 |
IntAct
26 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| BNIP1 | NBAS | psi-mi:“MI:0914”(association) | 0.640 |
| ATP6V1C2 | ATP6V1G1 | psi-mi:“MI:0914”(association) | 0.640 |
| ATP6V1B2 | ATP6V1G1 | psi-mi:“MI:0914”(association) | 0.530 |
| RPN1 | APBB1 | psi-mi:“MI:0914”(association) | 0.530 |
| ZNRD2 | MYO9A | psi-mi:“MI:0914”(association) | 0.530 |
| ATP6V1G2 | ATP6V1B1 | psi-mi:“MI:0914”(association) | 0.530 |
| SFPQ | WDR7 | psi-mi:“MI:0915”(physical association) | 0.400 |
| RYBP | FAM186A | psi-mi:“MI:0914”(association) | 0.350 |
| MAPT | SHTN1 | psi-mi:“MI:0914”(association) | 0.350 |
| ITM2B | ILVBL | psi-mi:“MI:0914”(association) | 0.350 |
| ATP6V1E1 | ATP6V1D | psi-mi:“MI:0914”(association) | 0.350 |
| ATP6V1F | MID1 | psi-mi:“MI:0914”(association) | 0.350 |
| ATP6V1G1 | MRPL3 | psi-mi:“MI:0914”(association) | 0.350 |
| ATP6V1H | ATP6V1G1 | psi-mi:“MI:0914”(association) | 0.350 |
| DDOST | ATL3 | psi-mi:“MI:0914”(association) | 0.350 |
| OST4 | ATL3 | psi-mi:“MI:0914”(association) | 0.350 |
| DMXL1 | LLGL1 | psi-mi:“MI:0914”(association) | 0.350 |
| WDR7 | DMXL2 | psi-mi:“MI:0914”(association) | 0.350 |
| atp6v1g_human | HSPA8 | psi-mi:“MI:0914”(association) | 0.350 |
| UGGT2 | MAP2K7 | psi-mi:“MI:0914”(association) | 0.350 |
| ROGDI | ATP2A1 | psi-mi:“MI:0914”(association) | 0.350 |
| ROGDI | NUDT3 | psi-mi:“MI:0914”(association) | 0.350 |
| TGOLN2 | BLTP3B | psi-mi:“MI:2364”(proximity) | 0.270 |
BioGRID (103): FRMD6 (Two-hybrid), WDR7 (Affinity Capture-MS), WDR7 (Affinity Capture-MS), WDR7 (Affinity Capture-MS), WDR7 (Affinity Capture-MS), WDR7 (Affinity Capture-MS), WDR7 (Negative Genetic), WDR7 (Negative Genetic), WDR7 (Negative Genetic), WDR7 (Negative Genetic), WDR7 (Negative Genetic), WDR7 (Negative Genetic), WDR7 (Negative Genetic), WDR7 (Negative Genetic), WDR7 (Negative Genetic)
ESM2 similar proteins: A0A0G2KIZ8, A0A1L8GXY4, A0A571BF63, A0A8M9QN10, A2CEI4, A2RRP1, A4D1P6, A6H8T2, A9X1C6, B0FXQ5, B1WC10, B2KIQ4, B2RY71, B2RYI0, B7FF09, B7FF12, E9PYY5, F1QHZ6, Q1LXZ7, Q2HJE1, Q3UMY5, Q402B2, Q4V8G4, Q5R6T6, Q5RE88, Q5U1Z0, Q5VTH9, Q5XIZ9, Q5ZLL7, Q6DFC6, Q6DTM3, Q6GPB9, Q6P2C0, Q6TEN6, Q7TMQ7, Q7ZVR1, Q8BMG7, Q8BX17, Q8C147, Q8IWG1
Diamond homologs: D3YYM4, Q3MJ13, Q5RFQ4, Q920I9, Q9ERH3, Q9Y4E6, A2QEV8, A4HUV2, B0XYC8, B6GZD3, F4IH25, O42858, O43071, P25382, P39706, P41838, Q00808, Q05AM5, Q08924, Q26544, Q2UQ34, Q32LN7, Q4P5F5, Q4QH39, Q4V7A0, Q4WX90, Q54KL5, Q54S59, Q5B464, Q5B8Y3, Q5ZJH5, Q6GMD2, Q6P5M2, Q6PBD6, Q7KWK5, Q93847, Q9ERF3, Q9GZS3
SIGNOR signaling
1 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| WDR7 | “form complex” | “RAVE complex, DMXL1 variant” | binding |
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 39 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | 6 | 134.3× | 8e-11 |
| Insulin receptor recycling | 9 | 114.2× | 3e-15 |
| Transferrin endocytosis and recycling | 9 | 110.5× | 3e-15 |
| ROS and RNS production in phagocytes | 9 | 100.8× | 6e-15 |
| Amino acids regulate mTORC1 | 9 | 60.1× | 7e-13 |
| Ion channel transport | 10 | 32.0× | 1e-11 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| synaptic vesicle lumen acidification | 7 | 187.2× | 7e-13 |
| vacuolar acidification | 7 | 146.5× | 3e-12 |
| regulation of macroautophagy | 8 | 67.6× | 2e-11 |
| proton transmembrane transport | 6 | 53.5× | 7e-08 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
211 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 177 |
| Likely benign | 6 |
| Benign | 5 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
6910 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 18:56651573:ACAGG:A | donor_loss | 1.0000 |
| 18:56651574:CAGGT:C | donor_loss | 1.0000 |
| 18:56651575:AGGT:A | donor_loss | 1.0000 |
| 18:56651576:GGTAA:G | donor_loss | 1.0000 |
| 18:56651577:GTAA:G | donor_loss | 1.0000 |
| 18:56651578:T:A | donor_loss | 1.0000 |
| 18:56672491:TTTCA:T | acceptor_loss | 1.0000 |
| 18:56672492:TTCA:T | acceptor_loss | 1.0000 |
| 18:56672493:TCA:T | acceptor_loss | 1.0000 |
| 18:56672494:CA:C | acceptor_loss | 1.0000 |
| 18:56672495:A:AG | acceptor_gain | 1.0000 |
| 18:56672495:A:T | acceptor_loss | 1.0000 |
| 18:56672496:G:GG | acceptor_gain | 1.0000 |
| 18:56672496:G:GT | acceptor_loss | 1.0000 |
| 18:56672671:GCAA:G | donor_gain | 1.0000 |
| 18:56672675:G:GG | donor_gain | 1.0000 |
| 18:56672679:G:GG | donor_gain | 1.0000 |
| 18:56679435:GTGG:G | donor_gain | 1.0000 |
| 18:56679437:GG:G | donor_gain | 1.0000 |
| 18:56679438:GG:G | donor_gain | 1.0000 |
| 18:56681070:G:GT | donor_gain | 1.0000 |
| 18:56681071:A:T | donor_gain | 1.0000 |
| 18:56682666:G:A | acceptor_gain | 1.0000 |
| 18:56682669:A:AG | acceptor_gain | 1.0000 |
| 18:56682669:AT:A | acceptor_gain | 1.0000 |
| 18:56682670:T:G | acceptor_gain | 1.0000 |
| 18:56682670:T:TA | acceptor_gain | 1.0000 |
| 18:56682674:T:G | acceptor_gain | 1.0000 |
| 18:56682674:TGTA:T | acceptor_loss | 1.0000 |
| 18:56682677:A:AG | acceptor_gain | 1.0000 |
AlphaMissense
9705 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 18:56672552:T:A | W13R | 1.000 |
| 18:56672552:T:C | W13R | 1.000 |
| 18:56679422:A:C | S84R | 1.000 |
| 18:56679424:T:A | S84R | 1.000 |
| 18:56679424:T:G | S84R | 1.000 |
| 18:56681326:T:A | W94R | 1.000 |
| 18:56681326:T:C | W94R | 1.000 |
| 18:56681349:T:G | C101W | 1.000 |
| 18:56686000:T:A | W189R | 1.000 |
| 18:56686000:T:C | W189R | 1.000 |
| 18:56695103:T:C | L421P | 1.000 |
| 18:56695115:G:C | R425P | 1.000 |
| 18:56695169:T:C | L443P | 1.000 |
| 18:56696244:T:A | W454R | 1.000 |
| 18:56696244:T:C | W454R | 1.000 |
| 18:56696338:T:C | L485P | 1.000 |
| 18:56696347:G:A | G488E | 1.000 |
| 18:56696373:T:A | W497R | 1.000 |
| 18:56696373:T:C | W497R | 1.000 |
| 18:56718001:A:T | D539V | 1.000 |
| 18:56718006:T:C | S541P | 1.000 |
| 18:56718087:T:A | W568R | 1.000 |
| 18:56718087:T:C | W568R | 1.000 |
| 18:56718109:T:C | L575P | 1.000 |
| 18:56718142:T:A | V586D | 1.000 |
| 18:56718144:T:A | W587R | 1.000 |
| 18:56718144:T:C | W587R | 1.000 |
| 18:56718146:G:C | W587C | 1.000 |
| 18:56718146:G:T | W587C | 1.000 |
| 18:56731395:G:C | R596P | 1.000 |
dbSNP variants (sampled 300 via entrez): RS1000004806 (18:56825556 G>C), RS1000010219 (18:56709820 C>T), RS1000011211 (18:57000632 A>T), RS1000015725 (18:56842861 G>A,C), RS1000030730 (18:56754397 A>C,G), RS1000045450 (18:56682569 A>C), RS1000045955 (18:56663360 A>C), RS1000061669 (18:56795648 A>G), RS1000071464 (18:56897374 A>C,G), RS1000077806 (18:57020934 G>A,C,T), RS1000078412 (18:56949556 G>A,T), RS1000079316 (18:56667182 T>C), RS1000082595 (18:56890553 A>G), RS1000089026 (18:56842565 C>T), RS1000097932 (18:56812117 T>C)
Disease associations
OMIM: gene MIM:613473 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
8 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST000267_2 | Multiple sclerosis (age of onset) | 4.000000e-06 |
| GCST001313_6 | Depression and alcohol dependence | 8.000000e-06 |
| GCST002682_14 | Tourette’s syndrome or obsessive-compulsive disorder | 4.000000e-06 |
| GCST006624_123 | Systolic blood pressure | 3.000000e-17 |
| GCST009379_221 | Type 2 diabetes | 3.000000e-08 |
| GCST011985_5 | Congenital heart disease (septal defects) | 2.000000e-08 |
| GCST012490_109 | Femur bone mineral density x serum urate levels interaction | 1.000000e-08 |
| GCST012490_270 | Femur bone mineral density x serum urate levels interaction | 2.000000e-09 |
EFO canonical traits (3, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004847 | age at onset |
| EFO:0006335 | systolic blood pressure |
| EFO:0004531 | urate measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
PharmGKB variants
1 variants.
| Variant | Genes | Level | Score | #Clin annots | Drugs |
|---|---|---|---|---|---|
| rs501415 | WDR7 | 0.00 | 0 |
CTD chemical–gene interactions
33 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Benzo(a)pyrene | affects methylation, decreases expression | 6 |
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | decreases expression | 3 |
| potassium chromate(VI) | affects cotreatment, decreases expression | 2 |
| Acetaminophen | decreases expression, increases expression | 2 |
| Aflatoxin B1 | affects expression, increases methylation | 2 |
| Cadmium Chloride | decreases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| FR900359 | increases phosphorylation | 1 |
| chloroacetaldehyde | decreases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| beta-lapachone | decreases expression | 1 |
| sodium arsenite | increases expression | 1 |
| aflatoxin B2 | decreases methylation | 1 |
| epigallocatechin gallate | affects cotreatment, decreases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| chromium hexavalent ion | decreases expression | 1 |
| deguelin | decreases expression | 1 |
| (+)-JQ1 compound | increases expression | 1 |
| Rosiglitazone | decreases expression | 1 |
| Arsenic Trioxide | increases response to substance | 1 |
| Antimycin A | decreases expression | 1 |
| Atrazine | decreases expression | 1 |
| Caffeine | affects phosphorylation | 1 |
| Diazinon | increases methylation | 1 |
| Ivermectin | affects expression | 1 |
| Oxygen | decreases expression | 1 |
| Quercetin | decreases expression | 1 |
| Tretinoin | increases expression | 1 |
| Urethane | increases expression | 1 |
| Valproic Acid | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): alcohol dependence, heart septal defect, multiple sclerosis, obsessive-compulsive disorder